Endogenous Bufadienolide, Blood Pressure and Alcohol Withdrawal

Author(s): Vladimir A. Kashkin*, Alexei Y. Egorov, Evgeniy M. Krupitsky, Alexei Y. Bagrov*

Journal Name: Current Hypertension Reviews

Volume 17 , Issue 2 , 2021

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background and Objective: Previously, it was demonstrated that marinobufagenin (MBG) is implicated in the development of ethanol withdrawal in rats. It has been shown that ethanol withdrawal is associated with a pressor response in the alcoholics. We hypothesized that elevated levels of sodium pump ligand, MBG, would underline the increase in systolic blood pressure during alcohol withdrawal in humans.

Methods: The cohort included 9 patients with the diagnosis “alcohol dependence syndrome” (F10.(1-3) according to ICD-10). The blood samples for measurement of MBG concentration were collected from the subjects on the first day of withdrawal and after 7 days treatment of the abstinence. Arterial blood pressure was measured via plethysmography at the same time points.

Results: The beginning of the alcoholic abstinence was associated with the rise of arterial blood pressure with enhanced levels of plasma MBG. At day 7 following withdrawal, the systolic blood pressure and MBG levels were decreased to normal values.

Conclusion: The development of alcohol withdrawal is accompanied by an increase in arterial blood pressure, which is associated with increased plasma MBG concentration.

Keywords: Alcohol withdrawal, systolic blood pressure, marinobufagenin, human, endogenous bufadienolide, plasma MBG.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 19 August, 2020
Page: [170 - 173]
Pages: 4
DOI: 10.2174/1573402116999200819162306
Price: $65

Article Metrics

PDF: 426